Safety of the 15-valent pneumococcal conjugate vaccine: A phase I clinical trial

References

• Hamborsky J, Kroger A, S W. Centers for disease control and prevention. epidemiology and prevention of vaccine-preventable diseases. Washington D.C: Public Health Foundation; 2015.
   Google Scholar
• Pick H, Daniel P, Rodrigo C, Bewick T, Ashton D, Lawrence H, Baskaran V, Edwards-Pritchard RC, Sheppard C, Eletu SD, et al. Pneumococcal serotype trends, surveillance and risk factors in UK adult pneumonia, 2013–18. Thorax. 2020;75(1):1–7. doi:10.1136/thoraxjnl-2019-213725. PMID: 31594801.
   Web of Science ®Google Scholar
• O’Brien KL, Wolfson LJ, Watt JP, Henkle E, Deloria-Knoll M, McCall N, Lee E, Mulholland K, Levine OS, Cherian T, et al. Burden of disease caused by streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet. 2009;374(9693):893–902. doi:10.1016/S0140-6736(09)61204-6. PMID: 19748398.
   PubMed Web of Science ®Google Scholar
• Well-Olivier C, Van der Linden M, Schutter I, Dagan R, Mantovani L. Prevention of pneumococcal diseases in the post-seven valent vaccine era. A European perspective. BMC Infect Dis. 2012;12(1):207. doi:10.1186/1471-2334-12-207. PMID: 22954038.
   PubMedGoogle Scholar
• World Health Organization. Pneumococcal vaccines WHO position paper–2012. Wkly Epidemiol Rec. 2012;87(14):129–144. PMID: 24340399.
   PubMedGoogle Scholar
• Niederman MS, Folaranmi T, Buchwald UK, Musey L, Cripps AW, Johnson KD. Efficacy and effectiveness of a 23-valent polysaccharide vaccine against invasive and non-invasive pneumococcal disease and related outcomes. A review of available evidence. Expert Rev Vaccines. 2021;20(3):243–256. doi:10.1080/14760584.2021.1880328. PMID: 33478306.
   PubMed Web of Science ®Google Scholar
• Simonetti AF, Viasus D, Garcia-Vidal C, Carratalà J. Management of community-acquired pneumonia in older adults. Ther Adv Infect Dis. 2014;2(1):3–16. doi:10.1177/2049936113518041. PMID: 25165554.
   PubMedGoogle Scholar
• Platt HL, Cardona JF, Haranaka M, Schwartz HI, Narejos Perez S, Dowell A, Chang CJ, Dagan R, Tamms GM, Sterling T, et al. A phase 3 trial of safety, tolerability, and immunogenicity of V114, 15-valent pneumococcal conjugate vaccine, compared with 13-valent pneumococcal conjugate vaccine in adults 50 years of age and older (PNEU-AGE). Vaccine. 2022;40:162–172. doi:10.1016/j.vaccine.2021.08.049. PMID: 34507861.
   PubMed Web of Science ®Google Scholar
• Redin A, Ciruela P, de Sevilla MF, Gomez-Bertomeu F, Gonzalez-Peris S, Benitez MA, Trujillo G, Diaz A, Jou E, Izquierdo C, et al. Serotypes and clonal composition of streptococcus pneumoniae isolates causing IPD in children and adults in Catalonia before 2013 to 2015 and after 2017 to 2019 systematic introduction of PCV13. Microbiol Spectr. 2021;9(3):e0115021. Dec 22. doi: 10.1128/Spectrum.01150-21. PMID: 34878302.
   PubMed Web of Science ®Google Scholar
• Pitsiou GG, Kioumis IP. Pneumococcal vaccination in adults: does it really work? Respir Med. 2011;105(12):1776–1783. doi:10.1016/j.rmed.2011.07.008. PMID: 21816596.
   PubMed Web of Science ®Google Scholar
• Black S, Shinefield H, Fireman B, Lewis E, Ray P, Hansen JR, Elvin L, Ensor KM, Hackell J, Siber G, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California kaiser permanente vaccine study center group. Pediatr Infect Dis J. 2000;19(3):187–195. doi:10.1097/00006454-200003000-00003. PMID: 12907008.
   PubMed Web of Science ®Google Scholar
• Moore MR, Link-Gelles R, Schaffner W, Lynfield R, Lexau C, Bennett NM, Petit S, Zansky SM, Harrison LH, Reingold A, et al. Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population based surveillance. Lancet Infect Dis. 2015;15(3):301–309. doi:10.1016/S1473-3099(14)71081-3. PMID: 25656600.
   PubMed Web of Science ®Google Scholar
• Domínguez Á, Ciruela P, Hernández S, García-García JJ, Moraga F, de Sevilla MF, Selva L, Coll F, Muñoz-Almagro C, Planes AM, et al. Effectiveness of the 13-valent pneumococcal conjugate vaccine in preventing invasive pneumococcal disease in children aged 7-59 months. A matched case-control study. PLoS One. 12:e018319115. doi:10.1371/journal.pone.0183191. PMID: 28806737.
   Web of Science ®Google Scholar
• Muñoz-Almagro C, Jordan I, Gene A, Latorre C, Garcia-Garcia J, Pallares R. Emergence of invasive pneumococcal disease caused by nonvaccine serotypes in the era of 7-valent conjugate vaccine. Clin Infect Dis. 2008;46:174–182. doi:10.1086/524660. PMID: 18171247.
   PubMed Web of Science ®Google Scholar
• Falkenhorst G, Remschmidt C, Harder T, Hummers-Pradier E, Wichmann O, Bogdan C. Effectiveness of the 23-Valent Pneumococcal Polysaccharide Vaccine (PPV23) against pneumococcal disease in the elderly: systematic review and meta-analysis. PLoS One. 2017;12(1):e0169368. doi:10.1371/journal.pone.0169368. eCollection 2017. PMID: 28061505.
   PubMed Web of Science ®Google Scholar
• Maruyama T, Taguchi O, Niederman MS, Morser J, Kobayashi H, Kobayashi T, D’Alessandro-Gabazza C, Nakayama S, Nishikubo K, Noguchi T, et al. Efficacy of 23-valent pneumococcal vaccine in preventing pneumonia and improving survival in nursing home residents: double blind, randomised and placebo controlled trial. Bmj. 2010;340(1):c1004. doi:10.1136/bmj.c1004. PMID: 20211953.
   PubMedGoogle Scholar
• Moberley S, Holden J, Tatham DP, Andrews RM. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev. 2013;(1):Cd000422. doi:10.1002/14651858.CD000422.pub2. PMID: 18253977.
   PubMed Web of Science ®Google Scholar
• Vila-Corcoles A, Salsench E, Rodriguez-Blanco T, Ochoa-Gondar O, de Diego C, Valdivieso A, Hospital I, Gomez-Bertomeu F, Raga X. Clinical effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumonia in middle-aged and older adults: a matched case-control study. Vaccine. 2009;27(10):1504–1510. doi:10.1371/journal.pmed.1003326. PMID: 33095759.
   PubMed Web of Science ®Google Scholar
• Shapiro ED, Berg AT, Austrian R, Schroeder D, Parcells V, Margolis A, Adair RK, Clemens JD. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med. 1991;325(21):1453–1460. doi:10.1056/NEJM199111213252101. PMID: 1944423.
   PubMed Web of Science ®Google Scholar
• Pichichero ME. Protein carriers of conjugate vaccines: characteristics, development, and clinical trials. Hum Vaccines Immunotherapeutics. 2013;9(12):2505–2523. doi:10.4161/hv.26109. PMID: 23955057.
   PubMed Web of Science ®Google Scholar
• Klugman KP, Madhi SA, Huebner RE, Kohberger R, Mbelle N, Pierce N. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med. 2003;349(14):1341–1348. doi:10.1056/NEJMoa035060. PMID: 14523142.
   PubMed Web of Science ®Google Scholar
• O’Brien, KL. Pneumococcal regional serotype distribution for pneumococcal AMC TPP (Codebook to assess whether a pneumococcal vaccine meets the pneumococcal AMC target product profile for regional vaccine serotype coverage). Prepared by GAVI’s PneumoADIP. et al.11/30/2008.
   Google Scholar
• Black SB, Shineford HR, Ling J, Hansen S, Fireman B, Spring D, Noyes J, Lewis E, Ray P, Lee J, et al. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia. Pediatr Infect Dis J. 2002;21(9):810–815. doi:10.1097/00006454-200209000-00005. PMID: 12352800.
   PubMed Web of Science ®Google Scholar
• French N, Gordon SB, Mwalukomo T, White SA, Mwafulirwa G, Longwe H, Mwaiponya M, Zijlstra EE, Molyneux ME, Gilks CF, et al. A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults. N Engl J Med. 2010;362(9):812–822. PMID: 27895845.
   PubMed Web of Science ®Google Scholar
• Andrews NJ, Waight PA, Burbidge P, Pearce E, Roalfe L, Zancolli M, Slack M, Ladhani SN, Miller E, Goldblatt D, et al. Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a post licensure indirect cohort study. Lancet Infect Dis. 2014;14(9):839–846. doi:10.1016/S1473-3099(14)70822-9. PMID: 25042756.
   PubMed Web of Science ®Google Scholar
• Weinberger R, van der Linden M, Imöhl M, von Kries R. Vaccine effectiveness of PCV13 in a 3+1 vaccination schedule. Vaccine. 2016;34(18):2062–2065. doi:10.1016/j.vaccine.2016.02.043. PMID: 26920471.
   PubMed Web of Science ®Google Scholar
• Moore MR, Link-Gelles R, Schaffner W, Lynfield R, Holtzman C, Harrison LH, Zansky SM, Rosen JB, Reingold A, Scherzinger K, et al. Effectiveness of 13-valent pneumococcal conjugate vaccine for prevention of invasive pneumococcal disease in children in the USA: a matched case-control study. Lancet Respir Med. 2016;4(5):399–406. doi:10.1016/S2213-2600(16)00052-7. PMID: 26987984.
   PubMed Web of Science ®Google Scholar
• Pichichero M, Kaur R, Scott DA, Gruber W, Trammel J, Almudevar A, Center KJ. Effectiveness of 13-valent pneumococcal conjugate vaccination for protection against acute otitis media caused by streptococcus pneumoniae in healthy young children: a prospective observational study. Lancet Child Adolesc Health. 2018;2(8):561–568. doi:10.1016/S2352-4642(18)30168-8. PMID: 30119715.
   PubMedGoogle Scholar
• Guevara M, Barricarte A, Torroba L, Herranz M, Gil-Setas A, Gil F, Bernaola E, Ezpeleta C, Castilla J. Direct, indirect and total effects of 13-valent pneumococcal conjugate vaccination on invasive pneumococcal disease in children in Navarra, Spain, 2001 to 2014: cohort and case-control study. Euro Surveillance. 2016;21(14). doi:10.2807/1560-7917.ES.2016.21.14.30186. PMID: 27103428.
   PubMedGoogle Scholar
• Bonten MJM, Huijts SM, Bolkenbaas M, Webber C, Patterson S, Gault S, van Werkhoven CH, van Deursen AMM, Sanders EAM, Verheij TJM, et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med. 2015;372(12):1114–1125. doi:10.1056/NEJMoa1408544. PMID: 25785969.
   PubMed Web of Science ®Google Scholar
• McLaughlin JM, Jiang Q, Isturiz RE, Sings HL, Swerdlow DL, Gessner BD, Carrico RM, Peyrani P, Wiemken TL, Mattingly WA, et al. Effectiveness of 13-valent pneumococcal conjugate vaccine against hospitalization for community-acquired pneumonia in older US adults: a test-negative design. Clin Infect Dis. 2018;67(10):1498–1506. doi:10.1093/cid/ciy312. PMID: 29790925.
   PubMed Web of Science ®Google Scholar
• Cannon K, Elder C, Young M, Scott DA, Scully IL, Baugher G, Peng Y, Jansen KU, Gruber WC, Watson W, et al. A trial to evaluate the safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine in populations of adults≧65 years of age with different prior pneumococcal vaccination. Vaccine. 2021;39(51):7494–7502. doi:10.1016/j.vaccine.2021.10.032. PMID: 34839993.
   PubMed Web of Science ®Google Scholar
• Ruiz-Aragón J, Márquez Peláez S, Molina-Linde JM, Grande-Tejada AM. Safety and immunogenicity of 13-valent pneumococcal conjugate vaccine in infants: a meta-analysis. Vaccine. 2013;31(46):5349–5358. doi:10.1016/j.vaccine.2013.09.008. PMID: 24055349.
   PubMed Web of Science ®Google Scholar